Alpha-synuclein seeding activity in postmortem tissues from patients with diffuse and isolated Lewy bodies

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064190%3A_____%2F26%3A10001461" target="_blank" >RIV/00064190:_____/26:10001461 - isvavai.cz</a>

Result on the web

<a href="https://doi.org/10.1186/s40478-025-02195-6" target="_blank" >https://doi.org/10.1186/s40478-025-02195-6</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1186/s40478-025-02195-6" target="_blank" >10.1186/s40478-025-02195-6</a>

Result language

angličtina

Original language name

Alpha-synuclein seeding activity in postmortem tissues from patients with diffuse and isolated Lewy bodies

Original language description

We have evaluated the diagnostic potential of the seeding amplification assay (SAA) in detecting alpha-synuclein seeding activity in postmortem brain and cerebrospinal fluid (CSF) samples from patients with primary and co-pathology alpha-synucleinopathies. Moreover, we investigated potential SAA positivity in control samples which may suggest unrecognized co-pathology. A total of 15 brain and 14 CSF samples with definite dementia with Lewy bodies (DLB, n = 6), Alzheimers disease with amygdala Lewy body (AD/ALB, n = 3), and patients with concomitant Creutzfeldt-Jakob disease and Lewy body pathology (CJD/LBP, n = 6) comorbidity were tested for alpha-synuclein seeding activity using SAA assay utilizing recombinant alpha-synuclein (WT) with N-terminal His-tag. Control samples consisted of other neurodegenerative diseases (n = 17 for brain and n = 18 for CSF samples) and healthy corneal donors (n = 17). The analysis of seeding activity in brain samples suggested 100% sensitivity and 91.2% specificity. Five out of 34 brain control samples gave a positive SAA outcome. However, upon reevaluation, two of these samples were reclassified as Alzheimers disease (AD) with synucleinopathy co-pathology. The analysis of CSF also suggested 100% sensitivity and 94.4% specificity, although dilution of some samples was necessary to decrease the effect of inhibitors. We report a good performance of the SAA not only in postmortem samples from primary synucleinopathies with advanced pathology, but also in co-pathology synucleinopathies with isolated Lewy bodies in the amygdala in AD cases. Our findings highlight the importance of careful diagnostic evaluation in AD patients, where co-existing synucleinopathy may otherwise go unrecognized.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30103 - Neurosciences (including psychophysiology)

Project

<a href="/en/project/NU23-04-00173" target="_blank" >NU23-04-00173: Utilization of RT-QuIC assay for improvement of diagnostics of neurodegenerative diseases: Prospective and retrospective studies</a><br>

Continuities

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2026

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

ACTA NEUROPATHOLOGICA COMMUNICATIONS

ISSN

2051-5960

e-ISSN

—

Volume of the periodical

14

Issue of the periodical within the volume

1

Country of publishing house

GB - UNITED KINGDOM

Number of pages

14

Pages from-to

nestránkováno

UT code for WoS article

001656348000001

EID of the result in the Scopus database

2-s2.0-105026929460